J 2004

Amplification and overexpression of HER-2/neu in invasive ductal carcinomas of the pancreas and pancreatic intraepithelial neoplasms and the relationship to the expression of p21(WAF1/CIP1)

HERMANOVÁ, Markéta, Zdeněk LUKÁŠ, Rudolf NENUTIL, Jan BRÁZDIL, Iva KROUPOVÁ et. al.

Basic information

Original name

Amplification and overexpression of HER-2/neu in invasive ductal carcinomas of the pancreas and pancreatic intraepithelial neoplasms and the relationship to the expression of p21(WAF1/CIP1)

Name in Czech

Amplifikace a overexprese HER-2/neu v invazivních duktálních karcinomech pankreatu a v pankreatických intraepiteliálních neoplaziích a jejich vztah k expresi p21(WAF1/CIP1)

Authors

HERMANOVÁ, Markéta (203 Czech Republic, guarantor), Zdeněk LUKÁŠ (203 Czech Republic), Rudolf NENUTIL (203 Czech Republic), Jan BRÁZDIL (203 Czech Republic), Iva KROUPOVÁ (203 Czech Republic), Leoš KŘEN (203 Czech Republic), Marie PAZOURKOVÁ (203 Czech Republic), Miloš RŮŽIČKA (203 Czech Republic) and Petr DÍTĚ (203 Czech Republic)

Edition

Neoplasma, SLOVAKIA, VEDA, SLOVAK ACADEMY SCIENCES, 2004, 0028-2685

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30200 3.2 Clinical medicine

Country of publisher

Slovakia

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 0.822

RIV identification code

RIV/00216224:14330/04:00018978

Organization unit

Faculty of Informatics

UT WoS

000221307400002

Keywords in English

adenocarcinoma; pancreas; HER-2/neu; p21; immunohistochemistry; FISH
Změněno: 22/6/2009 06:43, prof. MUDr. Markéta Hermanová, Ph.D.

Abstract

V originále

Overexpression of p21(WAF1/CIP1)seems to be HER-2/neu independent based on our results. Expression of HER-2/neu is growing according to grade of the ductal lesion and overexpression of HER-2/neu was demonstrated in 18% carcinomas. Two of 9 carcinomas with overexpression of HER-2/neu showed the amplification of HER-2/neu.

In Czech

Overexprese p21(WAF1/CIP1) je nezávislá na HER-2/neu dle našich výsledků. Exprese HER-2/neu narůstá podle gradu duktální léze a overexprese HER-2/neu byla prokázána v 18% karcinomů. Jen 2 z 9 karcinomů s overexpresí HER-2/neu měly amplifikaci tohoto genu.